Thyrocare

Tests you can trust

**Name** : Varsha Charankar (42Y/F)

**Date** : 17 Sep 2025

**Test Asked** : C153, C125 + 1 Others

**Report Status:** Complete Report


**First National Diagnostic Chain** to have **100% of its Labs with NABL Accreditation#**

98% Reports released within 06 Hours of sample reaching the lab+

9 out of 10 Doctors Trust that Thyrocare reports are Accurate & Reliable*

1200+ Tests & Profiles

Temperature-Controlled Sample Logistics

Unique Barcode Tracking

Fully Automated Machines Inspected Daily

Abnormal Values Re-Checked Twice

Reports Verified By Expert MD Pathologists Stationed at Every Lab

## Your reports are digitally verifiable

**Scan the QR code inside the report to check authenticity of reported values**

*QR code will remain active for 30 days from report release date*

Accredited by

NABL From 2005#

ISO 9001: 2015 - From 2015

CAP From 2007~

**Processed At :**
D-37/1,TTC MIDC,Turbhe, Navi Mumbai - 400703

Thyrocare
Tests you can trust

**Thyrocare Technologies Limited**, D-37/3, TTC MIDC, Turbhe, Navi Mumbai - 400 703. 9870666333 wellness@thyrocare.com

*First National Diagnostic Chain to have 100% of its Labs with NABL Accreditation#*

| | | | |
|---|---|---|---|
| Patient Name | : **VARSHA CHARANKAR (42Y/F)** | Tests Done | : **C153,C125,T3-T4-USTSH** |
| Referred By | : **SELF** | | |
| Sample Collected At | : **MyMDDr, Ganga Cascade, Office No. 04, Lane 5 A, North Main Road, Koregaon Park,** | | |

## Report Availability Summary

**Note:** Please refer to the table below for status of your tests.

**3** Ready | **0** Ready with Cancellation | **0** Processing | **0** Cancelled in Lab

| TEST DETAILS | REPORT STATUS |
|---|---|
| T3-T4-USTSH | Ready |
| CA-125 | Ready |
| CA 15.3 | Ready |

**Processed At :**
D-37/1,TTC MIDC,Turbhe, Navi Mumbai - 400703

CAP ACCREDITED
COLLEGE of AMERICAN PATHOLOGISTS

Thyrocare
Tests you can trust

**Thyrocare Technologies Limited**, D-37/3, TTC MIDC, Turbhe, Navi Mumbai - 400 703. 9870666333 wellness@thyrocare.com

*First National Diagnostic Chain to have 100% of its Labs with NABL Accreditation#*

| | | | |
|---|---|---|---|
| Patient Name | : **VARSHA CHARANKAR (42Y/F)** | Sample Collected on (SCT) | : **17 Sep 2025 17:16** |
| Referred By | : **SELF** | Sample Received on (SRT) | : **18 Sep 2025 03:31** |
| Sample Collected At | : **MyMDDr, Ganga Cascade, Office No. 04, Lane 5 A, North Main Road, Koregaon Park,** | Report Released on (RRT) | : **18 Sep 2025 06:16** |
| | | Sample Type \| Barcode | : **SERUM \| EJ123488** |

| TEST NAME | TECHNOLOGY | VALUE | UNITS |
|---|---|---|---|
| CA 15.3 | E.C.L.I.A | 10 | U/mL |

**Bio. Ref. Interval. :-**

<=28.5 U/mL

Clinical Significance:

1. CA 15.3 is elevated in about 30% of women with localized breast cancer and in about 75% of those with metastatic breast cancer
2. CA 15.3 also may be elevated in Healthy people and in individuals with other cancers or diseases, Such as Colorectal Cancer, Lung Cancer, Cirrhosis, Hepatitis, and Benign Breast Disease.
3. In General, the higher the CA 15-3 level the more advanced the Breast Cancer and the larger the Tumor Burden.
4.Samples should not be taken from patients receiving therapy with high biotin doses (i.e >5 mg/day) until atleast 8 hrs following the last biotin administration, as this may interfere with the result.
5. In few cases, interference due to extremely high titres of antibodies to analyte - specific antibodies, streptavidin or ruthenium can occur.
6. The results should be assessed in conjunction with patient medical history , clinical examination and other findings.

Reference -
- Duffy MJ, CA 15-3 and related mucins as circulating markers in breast cancer. Ann Clin Biochem, 1999:36:579-586
- Kit Insert

**Please correlate with clinical conditions.**
**Method:-** Fully Automated Electrochemiluminescence Sandwich Immunoassay

Tests Done : **CA 15.3,CA-125,T3-T4-USTSH**

**Dr Arshiya MD(Path)**

**Dr Ritika Khurana MD(Path)**

Scan QR to verify(valid for 30 days from release time)

| | | | |
|---|---|---|---|
| Patient Name | : **VARSHA CHARANKAR (42Y/F)** | Sample Collected on (SCT) | : **17 Sep 2025 17:16** |
| Referred By | : **SELF** | Sample Received on (SRT) | : **18 Sep 2025 03:31** |
| Sample Collected At | : **MyMDDr, Ganga Cascade, Office No. 04, Lane 5 A, North Main Road, Koregaon Park,** | Report Released on (RRT) | : **18 Sep 2025 06:16** |
| | | Sample Type \| Barcode | : **SERUM \| EJ123488** |

| TEST NAME | TECHNOLOGY | VALUE | UNITS |
|---|---|---|---|
| CA-125 | E.C.L.I.A | 5.23 | U/mL |

**Bio. Ref. Interval. :-**

<=35 U/mL

Clinical Significance:

1. CA-125 is used to monitor therapy during treatment for Ovarian Cancer. CA125 is also to detect or monitor whether there is a recurrence of cancer or malignancy after surgical removal of tumor or radiation therapy or chemotherapy (antineoplastic drugs).
2. This test is sometimes used to follow High-Risk women who have a family history of Ovarian Cancer. CA-125 may normally be increased in early pregnancy and during menstruation. It can also be increased in diseases such as Pelvic Inflammatory Disease or Endometriosis and sometimes in Hepatitis and Cirrhosis of the liver.
3. Samples should not be taken from patients receiving therapy with high biotin doses (i.e >5 mg/day) until atleast 8 hrs following the last biotin administration, as this may interfere with the result.
4. In few cases, interference due to extremely high titres of antibodies to analyte - specific antibodies, streptavidin or ruthenium can occur.
5. For Diagnostic Purpose, Results should always be assessed in conjunction with the patients medical history, Clinical Examination and other findings.

Reference
- O Brien TJ, Beard JB, Underwood LJ, et al. The CA 125 gene : an extracellular superstructure dominated by repeat sequences. Tumor Biol 2001; 22 (6): 348-366.
- Kit insert

**Please correlate with clinical conditions.**
**Method:-** Fully Automated Electrochemiluminescence Sandwich Immunoassay

Tests Done : **CA 15.3,CA-125,T3-T4-USTSH**

**Dr Arshiya MD(Path)**

**Dr Ritika Khurana MD(Path)**

**Processed At :**
D-37/1,TTC MIDC,Turbhe, Navi
Mumbai - 400703

Thyrocare
Tests you can trust

**Thyrocare Technologies Limited,** D-37/3, TTC MIDC, Turbhe, Navi Mumbai - 400 703. 9870666333 wellness@thyrocare.com

*First National Diagnostic Chain to have 100% of its Labs with NABL Accreditation#*

| | | | |
|---|---|---|---|
| Patient Name | : **VARSHA CHARANKAR (42Y/F)** | Sample Collected on (SCT) | : **17 Sep 2025 17:16** |
| Referred By | : **SELF** | Sample Received on (SRT) | : **18 Sep 2025 03:31** |
| Sample Collected At | : **MyMDDr, Ganga Cascade, Office No. 04, Lane 5 A, North Main Road, Koregaon Park,** | Report Released on (RRT) | : **18 Sep 2025 06:16** |
| | | Sample Type \| Barcode | : **SERUM \| EJ123488** |

| TEST NAME | TECHNOLOGY | VALUE | UNITS | Bio. Ref. Interval. |
|---|---|---|---|---|
| TOTAL TRIIODOTHYRONINE (T3) | E.C.L.I.A | 133 | ng/dL | 80-200 |
| TOTAL THYROXINE (T4) | E.C.L.I.A | 7.04 | µg/dL | 4.8-12.7 |
| TSH - ULTRASENSITIVE | E.C.L.I.A | 4.79 | µIU/mL | 0.54-5.30 |

**The Biological Reference Ranges is specific to the age group. Kindly correlate clinically.**

**Method :**

T3,T4 - Fully Automated Electrochemiluminescence Compitive Immunoassay
USTSH - Fully Automated Electrochemiluminescence Sandwich Immunoassay

Pregnancy reference ranges for TSH/USTSH :
Trimester || T3 (ng/dl) || T4 (µg/dl) || TSH/USTSH (µIU/ml)
1st || 83.9-196.6 || 4.4-11.5 || 0.1-2.5
2nd || 86.1-217.4 || 4.9-12.2 || 0.2-3.0
3rd || 79.9-186 || 5.1-13.2 || 0.3-3.5

References :

1. Carol Devilia, C I Parhon. First Trimester Pregnancy ranges for Serum TSH and Thyroid Tumor reclassified as Benign. Acta Endocrinol. 2016; 12(2) : 242 - 243
2. Kulhari K, Negi R, Kalra DK et al. Establishing Trimester specific Reference ranges for thyroid hormones in Indian women with normal pregnancy : New light through old window. Indian Journal of Contemporary medical research. 2019; 6(4)

**Disclaimer :**Results should always be interpreted using the reference range provided by the laboratory that performed the test. Different laboratories do tests using different technologies, methods and using different reagents which may cause difference. In reference ranges and hence it is recommended to interpret result with assay specific reference ranges provided in the reports. To diagnose and monitor therapy doses, it is recommended to get tested every time at the same Laboratory.

**~~ End of report ~~**

Tests Done : **CA 15.3,CA-125,T3-T4-USTSH**

**Dr Arshiya MD(Path)**

**Dr Ritika Khurana MD(Path)**

Scan QR to verify(valid for 30 days from release time)

## CONDITIONS OF REPORTING

- The reported results are for information and interpretation of the referring doctor only.
- It is presumed that the tests performed on the specimen belong to the patient; named or identified.
- Results of tests may vary from laboratory to laboratory and also in some parameters from time to time for the same patient.
- Should the results indicate an unexpected abnormality, the same should be reconfirmed.
- Only such medical professionals who understand reporting units, reference ranges and limitations of technologies should interpret results.
- This report is not valid for medico-legal purpose.
- Neither Thyrocare, nor its employees/representatives assume: (a) any liability, responsibility for any loss or damage that may be incurred by any person as a result of presuming the meaning or contents of the report, (b) any claims of any nature whatsoever arising from or relating to the performance of the requested tests as well as any claim for indirect, incidental or consequential damages. The total liability, in any case, of Thyrocare shall not exceed the total amount of invoice for the services provided and paid for.
- Thyrocare Discovery video link :- https://youtu.be/nbdYeRgYyQc

## EXPLANATIONS

- Majority of the specimen processed in the laboratory are collected by Pathologists and Hospitals we call them as "Clients".
- **Name** - The name is as declared by the client and recored by the personnel who collected the specimen.
- **Ref.Dr** - The name of the doctor who has recommended testing as declared by the client.
- **Labcode** - This is the accession number in our laboratory and it helps us in archiving and retrieving the data.
- **Barcode** - This is the specimen identity number and it states that the results are for the specimen bearing the barcode (irrespective of the name).
- **SCP** - Specimen Collection Point - This is the location where the blood or specimen was collected as declared by the client.
- **SCT** - Specimen Collection Time - The time when specimen was collected as declared by the client.
- **SRT** - Specimen Receiving Time - This time when the specimen reached our laboratory.
- **RRT** - Report Releasing Time - The time when our pathologist has released the values for Reporting.
- **Reference Range** - Means the range of values in which 95% of the normal population would fall.

## SUGGESTIONS

- Values out of reference range requires reconfirmation before starting any medical treatment.
- Retesting is needed if you suspect any quality shortcomings.
- Testing or retesting should be done in accredited laboratories.
- For suggestions, complaints, clinical support or feedback, write to us at **customersupport@thyrocare.com** or call us on **022-3090 0000**



+ *T&C Apply, #As on 5th December 2024 (Applicable for all company owned labs except Bhagalpur & Vijayawada),*

⋆ *As per survey on doctors' perception of laboratory diagnostics (IJARIIT, 2023), -Mumbai Reference Lab is CAP Accredited*